Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

doi:10.4254/wjh.v7.i19.2220

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8838)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

399

WORD

268

HTML

2696

Figures (1-4)

202

Tables (1-4)

174

Sum=3739

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

557

Download

1318

Sum=1875

Publishing Process of This Article

Item

Count

Browse

1151

Download

2073

Sum=3224

Sep 8, 2015 (publication date) through Jul 7, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Sep 8, 2015; 7(19): 2220-2228
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2220

Full Size Figure Download Figure

Figure 3 Cumulative hepatocellular carcinoma incidence after interferon therapy in the patient groups classified by the outcome of interferon therapy and alpha-fetoprotein values before and 1 year after interferon therapy. Cumulative hepatocellular carcinoma (HCC) incidence after interferon therapy was compared in groups of patients classified by the outcome of interferon therapy and alpha-fetoprotein values before and 1 year after interferon therapy using the Kaplan-Meier method. SVR: Sustained virological response; AFP: Alpha-fetoprotein.

Citation: Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015; 7(19): 2220-2228
URL: https://www.wjgnet.com/1948-5182/full/v7/i19/2220.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i19.2220